Stockreport

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

LakeShore Biopharma Co., Ltd - Ordinary Shares  (LSB) 
PDF Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoYAchieved gross profit of RMB 307.3 million, a growth of 39.1% YoYGross margin increased to 8 [Read more]